Page 9 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 9
Chapter 6b
Chapter 7
Chapter 8
Chapter 9 Addendum
Rituximab-CHOP With Early Rituximab Intensification 153 for Diffuse Large B-Cell Lymphoma: A Randomized
Phase III Trial of the HOVON and the Nordic
Lymphoma Group (HOVON-84). J Clin Oncol. 2020 Oct;38(29):3377-3387.
Treatment of patients with MYC rearrangement positive 179 large B-cell lymphoma with R-CHOP plus lenalidomide:
results of a multicenter HOVON phase II trial.
Haematologica. 2020 Dec;105(12):2805-2812.
Optimal timing and criteria of interim PET in DLBCL: 209 a comparative study of 1692 patients. Blood Adv. 2021 May;5(9):2375-2384.
Summary, discussion and future perspectives 235 Dutch summary / Nederlandse samenvatting 252 Acknowledgements / Dankwoord 259 Curriculum vitae 264 List of publications 265 List of abbreviations 268
